In a similar manner, member states must now pool their resources to address their shared geoeconomic concerns. To achieve ...

Product development highlights Alvotech announced that the European Medicines Agency (EMA) accepted a Marketing Authorization ...

Continuing to advance the pipeline and remain on-track to engage with the FDA on TP-04 (Papulopustular Rosacea) and TP-05 ...

September 2024: authorization received from The European Medicines Agency to initiate the INVINCIBLE-3 Study in Europe. September 2024: authorization from the Swiss Medic and the Swiss Ethics ...

is pleased to announce that the European Medicines Agency (the “EMA”) has granted Orphan Medicinal Product Designation for the Company’s ExoPTEN therapy, marking a significant step towards making this ...

Cardiol’s broad IP portfolio and regulatory pathway focus, including FDA and European Medicines Agency orphan designations, ...

Positive results from completed Phase 2 study of mavorixafor in chronic neutropenia (CN) announced todayPivotal Phase 3 trial of mavorixafor in ...

As the COVID-19 pandemic clearly demonstrated, health is an integral part of Europe’s security. That principle underpinned a ...